The price/operating cash flow metric for Dr Reddys Laboratories Ltd is higher than only 2.81% of stocks in our set with a positive cash flow.
With a year-over-year growth in debt of -41.16%, Dr Reddys Laboratories Ltd's debt growth rate surpasses just 6.79% of about US stocks.
Dr Reddys Laboratories Ltd's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is 211.85%, greater than the shareholder yield of 97.96% of stocks in our set.
Stocks that are quantitatively similar to RDY, based on their financial statements, market capitalization, and price volatility, are AGCO, OPK, HSTM, NSSC, and MOG.A.
RDY's SEC filings can be seen here. And to visit Dr Reddys Laboratories Ltd's official web site, go to www.drreddys.com.
Dr. Reddy's Laboratories operates as an integrated pharmaceutical company worldwide. It operates in three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The company was founded in 1984 and is based in Hyderabad, India.
RDY Price Forecast Based on DCF Valuation
DCF Fair Value Target:
Below please find a table outlining a discounted cash flow forecast for RDY, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Dr Reddys Laboratories Ltd ranked in the 92th percentile in terms of potential gain offered. More precisely, our analysis suggests the stock is undervalued by approximately 3279.5% on a DCF basis. The most interesting components of our discounted cash flow analysis for Dr Reddys Laboratories Ltd ended up being:
The business' balance sheet reveals debt to be 3% of the company's capital (with equity being the remaining amount). Approximately merely 9.69% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
RDY's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than 48.7% of tickers in our DCF set.
As a business, Dr Reddys Laboratories Ltd experienced a tax rate of about 0% over the past twelve months; relative to its sector (Healthcare), this tax rate is higher than merely 0% of stocks generating free cash flow.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
Want more companies with a valuation profile/forecast similar to that of Dr Reddys Laboratories Ltd? See ANIP, OMI, CYH, SUPN, and ACHC.
Dr. Reddy’s Laboratories (RDY) announces the launch of Cinacalcet Tablets, a therapeutic equivalent generic version of Amgen's Sensipar (cinacalcet) Tablets. According to IQVIA Health, the Sensipar had U.S. sales of ~$312M for twelve months ended July 2020. Dr. Reddy’s Cinacalcet Tablets are available in 30, 60, and 90 mg tablets....
Shares of Dr Reddy's Laboratories soared 10 percent to hit a record high of Rs 5,302.85 after the pharma company informed the settlement of their litigation with Celgene, a wholly-owned subsidiary of Bristol Myers Squibb, relating to patents for REVLIM (lenalidomide)
Dr. Reddy’s Laboratories (RDY) announces the launch of over-the-counter ((OTC)) Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% and 0.1%, the store-brand equivalents of Novartis' Pataday Once and Twice Daily Relief.Dr. Reddy’s Olopatadine Solution is indicated for the temporary relief of itchy eyes due to pollen, ragweed, grass, animal hair and dander...